SAB Biotherapeutics, Inc. (SABSW)
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States.
$0.02+0.27%
StockGlow Score
Bullish
BearishBullish
1 year ago-49.7%
The outlook
SAB Biotherapeutics, Inc. currently reads as bullish based on 100% of the way from its 52-week low to high. This is a snapshot of current market data, not a forecast.
What’s behind the score
52-week range100% of the way from its 52-week low to high
Market cap
—
52-wk high
$0.02
52-wk low
$0.01
50-day avg
—
200-day avg
—
Trailing P/E
0.1